Apotex Antitrust Claims Tossed From Daiichi IP Spat

Law360, New York (May 19, 2009, 12:00 AM EDT) -- Apotex Corp. will not be able to pursue antitrust claims against Daiichi Sankyo Co. Ltd. in a lawsuit over the Canadian drugmaker's attempts to make a generic version of Daiichi Sankyo's ear medicine Floxin Otic, a federal judge has ruled.

Judge Susan D. Wigenton of the U.S. District Court for the District of New Jersey on Monday found that the monopolization claims were based on the same allegations that formed the basis of Apotex's inequitable conduct claim, which another judge overseeing the case had already dismissed....
To view the full article, register now.